BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 24522083)

  • 21. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
    Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
    Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retrospective look at change in brain natriuretic peptide values in ambulatory patients with chronic heart failure.
    Wahla AS; Pascual R; Rafeq Z; Joseph J
    J Ayub Med Coll Abbottabad; 2012; 24(2):3-6. PubMed ID: 24397039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure.
    Fu S; Xie L; Li D; Ye P; Luo L
    Clin Interv Aging; 2015; 10():359-65. PubMed ID: 25670892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis.
    Savarese G; Musella F; D'Amore C; Vassallo E; Losco T; Gambardella F; Cecere M; Petraglia L; Pagano G; Fimiani L; Rengo G; Leosco D; Trimarco B; Perrone-Filardi P
    JACC Heart Fail; 2014 Apr; 2(2):148-58. PubMed ID: 24720923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of biomarkers to guide outpatient therapy of heart failure.
    DeBeradinis B; Januzzi JL
    Curr Opin Cardiol; 2012 Nov; 27(6):661-8. PubMed ID: 22941124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study.
    Gaggin HK; Mohammed AA; Bhardwaj A; Rehman SU; Gregory SA; Weiner RB; Baggish AL; Moore SA; Semigran MJ; Januzzi JL
    J Card Fail; 2012 Aug; 18(8):626-34. PubMed ID: 22858078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial.
    Lainchbury JG; Troughton RW; Strangman KM; Frampton CM; Pilbrow A; Yandle TG; Hamid AK; Nicholls MG; Richards AM
    J Am Coll Cardiol; 2009 Dec; 55(1):53-60. PubMed ID: 20117364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Value of brain natriuretic peptides in primary care patients with the clinical diagnosis of chronic heart failure.
    Zuber M; Cuculi F; Attenhofer Jost CH; Kipfer P; Buser P; Seifert B; Erne P
    Scand Cardiovasc J; 2009; 43(5):324-9. PubMed ID: 19247872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic Accuracy of Natriuretic Peptides for Heart Failure in Patients with Pleural Effusion: A Systematic Review and Updated Meta-Analysis.
    Han ZJ; Wu XD; Cheng JJ; Zhao SD; Gao MZ; Huang HY; Gu B; Ma P; Chen Y; Wang JH; Yang CJ; Yan ZH
    PLoS One; 2015; 10(8):e0134376. PubMed ID: 26244664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials.
    Brunner-La Rocca HP; Eurlings L; Richards AM; Januzzi JL; Pfisterer ME; Dahlström U; Pinto YM; Karlström P; Erntell H; Berger R; Persson H; O'Connor CM; Moertl D; Gaggin HK; Frampton CM; Nicholls MG; Troughton RW
    Eur J Heart Fail; 2015 Dec; 17(12):1252-61. PubMed ID: 26419999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.
    Bhardwaj A; Rehman SU; Mohammed A; Baggish AL; Moore SA; Januzzi JL
    Am Heart J; 2010 Apr; 159(4):532-538.e1. PubMed ID: 20362709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Worsening Renal Function during Management for Chronic Heart Failure with Reduced Ejection Fraction: Results From the Pro-BNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.
    Ibrahim NE; Gaggin HK; Rabideau DJ; Gandhi PU; Mallick A; Januzzi JL
    J Card Fail; 2017 Feb; 23(2):121-130. PubMed ID: 27469482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B-type natriuretic peptide in heart failure.
    Moe GW
    Curr Opin Cardiol; 2006 May; 21(3):208-14. PubMed ID: 16601459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk stratification with the use of serial N-terminal pro-B-type natriuretic peptide measurements during admission and early after discharge in heart failure patients: post hoc analysis of the PRIMA study.
    Eurlings LW; Sanders-van Wijk S; van Kraaij DJ; van Kimmenade R; Meeder JG; Kamp O; van Dieijen-Visser MP; Tijssen JG; Brunner-La Rocca HP; Pinto YM
    J Card Fail; 2014 Dec; 20(12):881-90. PubMed ID: 25175696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The predictive value of plasma biomarkers in discharged heart failure patients: role of plasma NT-proBNP.
    Leto L; Testa M; Feola M
    Minerva Cardioangiol; 2016 Apr; 64(2):157-64. PubMed ID: 26373781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome.
    Karlström P; Alehagen U; Boman K; Dahlström U;
    Eur J Heart Fail; 2011 Oct; 13(10):1096-103. PubMed ID: 21715446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of heart failure by amino terminal-pro-B-type natriuretic peptide and C-reactive protein in subjects with cerebrovascular disease.
    Campbell DJ; Woodward M; Chalmers JP; Colman SA; Jenkins AJ; Kemp BE; Neal BC; Patel A; MacMahon SW
    Hypertension; 2005 Jan; 45(1):69-74. PubMed ID: 15569851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study.
    Weiner RB; Baggish AL; Chen-Tournoux A; Marshall JE; Gaggin HK; Bhardwaj A; Mohammed AA; Rehman SU; Barajas L; Barajas J; Gregory SA; Moore SA; Semigran MJ; Januzzi JL
    Eur J Heart Fail; 2013 Mar; 15(3):342-51. PubMed ID: 23132825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy.
    Krauser DG; Lloyd-Jones DM; Chae CU; Cameron R; Anwaruddin S; Baggish AL; Chen A; Tung R; Januzzi JL
    Am Heart J; 2005 Apr; 149(4):744-50. PubMed ID: 15990762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
    Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
    J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.